Provectus Biopharmaceuticals is a clinical-stage biotech with no approved products and no product revenue. The company's entire pipeline is built around a single molecule: rose bengal sodium (RBS), a synthetic small molecule that Provectus synthesizes to near-100% purity as a pharmaceutical-grade API. Provectus claims to be the only entity that has advanced RBS into clinical trials. RBS can be administered via intratumoral injection, topically, or orally, and the company believes it works through multiple mechanisms including direct cell destruction and immune activation. The lead program, PV-10, is an intratumoral injection with clinical history in melanoma, liver cancers, and breast cancer; current trials at Moffitt Cancer Center focus on penile squamous cell carcinoma and pancreatic cancer. PH-10 is a topical formulation studied in psoriasis and atopic dermatitis. PV-305 is an ophthalmology formulation for infectious keratitis, developed through a collaboration with the University of Miami organized under a separate startup, VisiRose. Provectus funds operations through equity issuances and targets co-development partnerships or out-licensing deals — particularly for PV-10 — as nearer-term monetization paths, alongside the longer-dated goal of FDA approval. The company argues its proprietary synthesis process creates a defensible position, as commercially available rose bengal from third-party suppliers reportedly lacks the purity and consistency needed to meet regulatory standards.